Characterization of Epstein-Barr virus-infected B cells in patients with posttransplantation lymphoproliferative disease: disappearance after rituximab therapy does not predict clinical response.
Post-transplantation lymphoproliferative disease (PTLD) is associated with Epstein-Barr virus (EBV). Quantitative and qualitative differences in EBV in peripheral blood mononuclear cells (PBMCs) of PTLD patients and healthy controls were characterized. A quantitative competitive polymerase chain reaction (QC-PCR) technique confirmed previous reports that EBV load in PBMCs is increased in patients with PTLD in comparison with healthy seropositive controls (18 539 vs 335 per 10(6) PBMCs, P =.0002). The average frequency of EBV-infected cells was also increased (271 vs 9 per 10(6) PBMCs, P =.008). The distribution in numbers of viral genome copies per cell was assessed by means of QC-PCR at dilutions of PBMCs. There was no difference between PTLD patients and healthy controls. Similarly, no differences in the patterns of viral gene expression were detected between patients and controls. Finally, the impact of therapy on viral load was analyzed. Patients with a past history of PTLD who were disease-free (after chemotherapy or withdrawal of immunosuppression) at the time of testing showed viral loads that overlapped with those of healthy seropositive controls. Patients treated with rituximab showed an almost immediate and dramatic decline in viral loads. This decline occurred even in patients whose PTLD progressed during therapy. These results suggest that the increased EBV load in PBMCs of PTLD patients can be accounted for by an increase in the number of infected B cells in the blood. However, in terms of viral copy number per cell and pattern of viral gene expression, these B cells are similar to those found in healthy controls. Disappearance of viral load with rituximab therapy confirms the localization of viral genomes in PBMCs to B cells. However, the lack of relationship between the change in viral load and clinical response highlights the difference between EBV-infected PBMCs and neoplastic cells in PTLD.
Yang
J
J
Oncology Center, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA.
Tao
Q
Q
Flinn
I W
IW
Murray
P G
PG
Post
L E
LE
Ma
H
H
Piantadosi
S
S
Caligiuri
M A
MA
Ambinder
R F
RF
D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D016175:B-Lymphocyte Subsets / Q000821:virology*; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D004279:DNA, Viral / Q000097:blood; D018450:Disease Progression; D020031:Epstein-Barr Virus Infections / Q000097:blood / Q000473:pathology*; D005260:Female; D015967:Gene Expression Regulation, Viral; D016679:Genome, Viral; D004854:Herpesvirus 4, Human / Q000254:growth & development / Q000302:isolation & purification; D006801:Humans; D007116:Immunization, Passive; D007165:Immunosuppression Therapy / Q000009:adverse effects*; D017710:Lymphocyte Transfusion; D008232:Lymphoproliferative Disorders / Q000097:blood / Q000209:etiology / Q000473:pathology* / Q000628:therapy / Q000821:virology; D008297:Male; D008875:Middle Aged; D014411:Neoplastic Stem Cells / Q000821:virology*; D011183:Postoperative Complications / Q000097:blood / Q000209:etiology / Q000473:pathology* / Q000628:therapy / Q000821:virology; D011379:Prognosis; D020133:Reverse Transcriptase Polymerase Chain Reaction; D000069283:Rituximab; D014180:Transplantation; D016896:Treatment Outcome; D014412:Tumor Virus Infections / Q000473:pathology*; D019562:Viral Load; D014766:Viremia / Q000821:virology*; D014775:Virus Activation
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D004279:DNA, Viral; D000069283:Rituximab